CA125 and HE4: Measurement Tools for Ovarian Cancer

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Gynecologic and Obstetric Investigation

• Publication date

  2016-04-29

• Fields of study

  Medicine

• Identifiers
  DOI 10.1159/000442288PMID 27160726
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• HE4, Ca125 and ROMA algorithm for differential diagnosis between benign gynaecological diseases and ovarian cancer

  2014cited by this paper
• The use of HE4, CA125 and CA72-4 biomarkers for differential diagnosis between ovarian endometrioma and epithelial ovarian cancer

  2013cited by this paper
• Cancer statistics, 2013

  2013cited by this paper
• Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response

  2013cited by this paper
• HE4 combined with CA125: favorable screening tool for ovarian cancer

  2013cited by this paper
• Cancer statistics, 2012

  2012cited by this paper
• Elevated human epididymis protein 4 concentrations in chronic kidney disease

  2012cited by this paper
• Evaluation of ovarian cancer biomarkers HE4 and CA-125 in women presenting with a suspicious cystic ovarian mass

  2011cited by this paper
• Potential Markers for Detection and Monitoring of Ovarian Cancer

  2011cited by this paper
• Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases.

  2011cited by this paper
• Diagnostic performances of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases.

  2011cited by this paper
• Ovarian cancer screening and early detection in the general population.

  2011cited by this paper
• Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer.

  2010cited by this paper
• Results From Four Rounds of Ovarian Cancer Screening in a Randomized Trial

  2009cited by this paper
• Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus.

  2008cited by this paper
• Ovarian cancer screening with annual transvaginal sonography

  2007cited by this paper
• New tumor markers: CA125 and beyond

  2005cited by this paper
• The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma.

  2003cited by this paper
• Ovarian cancer screening in the general population: current status

  2001cited by this paper
• Screening for ovarian cancer: a pilot randomised controlled trial.

  1999cited by this paper
• Cancer statistics

  1989cited by this paper

• A diagnostic scoring system for differentiating between benign and malignant cystic ovarian tumors, utilizing imaging features and biomarkers

  2026cites this paper
• Ovarian Tumor Biomarkers: Correlation Between Tumor Type and Marker Expression, and Their Role in Guiding Therapeutic Strategies

  2025cites this paper
• Ovarian cancer biosensors: established glycoproteins to emerging molecular biomarkers.

  2025cites this paper
• Crucial computed tomography and magnetic resonance imaging findings of fallopian tubal tuberculosis for diagnosis: a retrospective study of 26 cases

  2024cites this paper
• Cancer antigen 153: A risk factor for ocular metastases in patients with breast cancer

  2024influential citation
• Pegylated liposomal doxorubicin in partially platinum-sensitive, platinum-resistant, or platinum-refractory ovarian cancer: a prospective study

  2024cites this paper
• Sarcoidosis presenting as multiple osseous lesions

  2024cites this paper
• The performance of Carbohydrate Antigen 125-Thomsen-nouveau and anti-Müllerian hormone combined with CA125, Human epididymis protein 4 and Risk of Malignancy Algorithm in diagnosis for patients with Epithelial ovarian cancer.

  2023cites this paper
• Revised Cut-Off Value of Human Epididymis Protein 4 Enhances Its Use as an Ovarian Tumor Marker

  2023cites this paper
• A colorimetric aptasensor for CA125 determination based on dual catalytic performance of CeO2 nanozyme confined in macroporous silica foam

  2023cites this paper
• Application of medical imaging in ovarian cancer: a bibliometric analysis from 2000 to 2022

  2023cites this paper
• Value of the risk of ovarian malignancy algorithm index in predicting the recurrence of epithelial ovarian cancer.

  2022cites this paper
• Multiple Biomarker Simultaneous Detection in Serum via a Nanomaterial-Functionalized Biosensor for Ovarian Tumor/Cancer Diagnosis

  2022cites this paper
• Pegylated Liposomal Doxorubicin for Recurrent Ovarian Cancer with Platinum Resistance or Refractoriness: Results from a Prospective Single-Arm Study

  2022cites this paper
• Clinical significance of CD38 and CD101 expression in PD-1+CD8+ T cells in patients with epithelial ovarian cancer

  2020cites this paper
• Liquid biopsy in ovarian cancer: Catching the silent killer before it strikes

  2020cites this paper
• The differential diagnostic value and clinical significance of serum HE4 in ovarian disease with elevated CA125

  2020cites this paper
• Clinical significance of CD 38 and CD 101 expression in PD ‐ 1 + CD 8 + T cells in patients with epithelial ovarian cancer

  2020cites this paper
• HE 4 antigen-autoantibody complexes complement CA 125 for detecting early stage ovarian cancer

  2019cites this paper
• Diagnostic accuracy of CA125 and HE4 in ovarian carcinoma patients and the effect of confounders on their serum levels.

  2019cites this paper
• Upregulated expression of serum exosomal miR-375 and miR-1307 enhance the diagnostic power of CA125 for ovarian cancer

  2019cites this paper
• Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review

  2019cites this paper
• The role of human epididymis protein 4 as a biomarker in gynecologic malignancies.

  2019cites this paper
• An electrochemical aptasensing platform for carbohydrate antigen 125 based on the use of flower-like gold nanostructures and target-triggered strand displacement amplification

  2019cites this paper
• Human epididymis protein 4 antigen‐autoantibody complexes complement cancer antigen 125 for detecting early‐stage ovarian cancer

  2019cites this paper
• A case of giant panda ovarian cancer diagnosis and histopathology

  2018cites this paper
• A quantitative performance study of two automatic methods for the diagnosis of ovarian cancer

  2018cites this paper
• Metabolomic profiling suggests long chain ceramides and sphingomyelins as a possible diagnostic biomarker of epithelial ovarian cancer.

  2018cites this paper
• Significance of serum CA-125 combined with CEA and HE-4 in diagnosis of epithelial ovarian cancer

  2018cites this paper
• Measurement of HE4 and CA125 and establishment of reference intervals for the ROMA index in the sera of pregnant women

  2018cites this paper
• Assessment of serum HE4 levels throughout the normal menstrual cycle

  2017cites this paper
• The role of novel biomarker HE4 in the diagnosis, prognosis and follow-up of ovarian cancer: a systematic review

  2017cites this paper